Development of Cagrilintide, a Long-Acting Amylin Analogue
Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl, Lauge Schäffer, Ulrich Sensfuß, Christian Poulsen, Morten Schlein, Ann Maria Kruse Hansen, Claus Jeppesen, Charlotta Dornonville de la Cour, Trine Ryberg Clausen, Eva Johansson, Simone Fulle, Rikke Bjerring Skyggebjerg, Kirsten Raun
Abstract
) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.
Topics & Concepts
AmylinChemistryAmyloid (mycology)Diabetes mellitusInsulinExenatideEndocrinologyPharmacologyInternal medicineMedicineType 2 diabetesIsletInorganic chemistryPancreatic function and diabetesAlzheimer's disease research and treatmentsDiabetes Treatment and Management